Your browser doesn't support javascript.
loading
Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.
Fizazi, K; Gravis, G; Flechon, A; Geoffrois, L; Chevreau, C; Laguerre, B; Delva, R; Eymard, J C; Rolland, F; Houede, N; Laplanche, A; Burcoveanu, D; Culine, S.
Affiliation
  • Fizazi K; Department of Cancer Medicine, Institut Gustave Roussy, Villejuif.
Ann Oncol ; 25(5): 987-91, 2014 May.
Article in En | MEDLINE | ID: mdl-24595454
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Testicular Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Neoplasms, Germ Cell and Embryonal / Neoplasm Recurrence, Local Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2014 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Testicular Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Neoplasms, Germ Cell and Embryonal / Neoplasm Recurrence, Local Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2014 Document type: Article Country of publication: